8-K: BrightSpring Q3 Revenue Soars, Boosts 2025 Outlook

BrightSpring Health Services reported strong third-quarter 2025 financial results, with significant revenue and Adjusted EBITDA growth, and raised its full-year 2025 revenue guidance.

Summary

• Revenues for the third quarter ended September 30, 2025, were $3,334 million, a 28.2% increase compared to $2,601 million in Q3 2024.
• Gross Profit reached $392 million, up 21.3% from $323 million in Q3 2024.
• Net income for Q3 2025 was $37.5 million, a significant improvement from a net loss of $25.7 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 was $160 million, marking a 37.2% increase from $117 million in Q3 2024.
• Full-year 2025 Revenue guidance was increased to $12,500 million to $12,800 million, representing 24.1% to 27.1% growth over 2024.
• Full-year 2025 Adjusted EBITDA guidance was reiterated at $605 million to $615 million, indicating 31.5% to 33.7% growth over 2024.
• The planned divestiture of the Community Living business to Sevita, announced on January 20, 2025, is now expected to close in Q1 2026.
• Leverage, as calculated under the First Lien Credit Agreement, was 3.31x at September 30, 2025.
• A secondary offering of 15,000,000 shares of common stock by Kohlberg Kravis Roberts & Co, L.P. and management, including a repurchase of 1,500,000 shares by BrightSpring, closed on October 22, 2025.

Sentiment

Score: 8

Explanation: Strong financial performance with significant revenue and Adjusted EBITDA growth, a turnaround to net income, and increased full-year revenue guidance indicate a very positive outlook despite a slight dip in prescription volume and a divestiture delay.

Positives

• Total Revenues increased by 28.2% to $3,334 million in Q3 2025.
• Achieved a net income of $37.5 million in Q3 2025, a turnaround from a net loss of $25.7 million in Q3 2024.
• Adjusted EBITDA grew by 37.2% to $160 million in Q3 2025.
• Increased full-year 2025 Revenue guidance to $12,500 million to $12,800 million.
• Pharmacy Solutions segment revenue grew by 31% and Provider Services segment revenue grew by 9% in Q3 2025.
• Pharmacy Solutions Revenue per script increased by 32% and Gross Profit per script increased by 31% in Q3 2025.
• Provider Services saw growth in Home Health Care average daily census (3%), Rehab Care persons served (11%), and Personal Care persons served (1%).

Negatives

• Pharmacy Solutions Prescriptions dispensed decreased by 1% in Q3 2025 compared to Q3 2024.

Risks

• Operating in a highly competitive industry.
• Inability to maintain relationships with existing patient referral sources or establish new ones.
• Changes to Medicare and Medicaid rates or payment methods.
• Cost containment initiatives of third-party payors, including post-payment audits.
• Implementation of alternative payment models and transition of Medicaid and Medicare beneficiaries to managed care organizations.
• Changes in the case mix of patients, payor mix, payment methodologies, and decisions of third-party organizations.
• Reliance on federal and state spending, budget decisions, and continuous governmental operations.
• Changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement.
• Changes in relationships with pharmaceutical suppliers, including drug availability or pricing.
• Reliance on the continual recruitment and retention of qualified personnel, including senior management.
• Compliance with or changes to federal, state, and local laws and regulations governing employment practices.
• Fluctuation of results of operations on a quarterly basis.
• Harm caused by labor relation matters.
• Limitations in ability to control reimbursement rates if unable to maintain or reduce costs.
• Delays in collection or non-collection of accounts receivable, particularly during business integration.
• Failure to manage growth effectively, inhibiting business plan execution or service quality.
• Ability to identify, successfully complete, and manage acquisitions, joint ventures, and other strategic initiatives, including the pending sale of the Community Living business.
• Ability to continue to provide consistently high quality of care.
• Maintenance of corporate reputation or emergence of adverse publicity.
• Contract continuance, expansion, and renewal with existing customers, including renewals at lower fee levels or reduced services.
• Effective investment in, implementation of improvements to, and proper maintenance of information technology and other business systems.
• Security breaches, loss of data, and other disruptions compromising sensitive information.
• Risks related to credit card payments and other payment methods.
• Potential substantial malpractice or other similar claims.
• Various risks related to governmental inquiries, regulatory actions, and whistleblower lawsuits.
• Current insurance program exposing to unexpected costs or uncovered losses.
• Factors outside of control requiring asset impairment of goodwill.
• A pandemic, epidemic, or outbreak of an infectious disease.
• Inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations.
• Inability to adequately protect intellectual property rights.
• Risks related to compliance with regulatory framework.
• Interests of KKR Stockholder potentially conflicting with other stockholders' interests.
• Substantial indebtedness.
• Significant changes in tax or trade policies, tariffs, or trade relations between the United States and other countries.
• Repurchases of common stock.

Future Outlook

BrightSpring Health Services increased its full-year 2025 Revenue guidance to a range of $12,500 million to $12,800 million, representing 24.1% to 27.1% growth. The company reiterated its Adjusted EBITDA guidance for the full year 2025 at $605 million to $615 million, indicating 31.5% to 33.7% growth. These projections exclude the Community Living business and the effects of any future closed acquisitions. Management expressed continued focus on driving best practices in operations and leveraging scale to provide quality and efficient services.

Management Comments

• "We are pleased with our third quarter organizational results."
• "The performance in the quarter and ongoing progress throughout the year have been underpinned by our ability to deliver high-quality, patient-centric, and lower-cost care across the Pharmacy and Provider segments."
• "We continue to focus on driving best practices in operations while leveraging our scale to provide quality and efficient services to complex populations in a timely, coordinated, and compassionate manner."
• "We remain focused on executing at a high level towards BrightSpring's goals for the remainder of 2025 and into 2026."

Industry Context

BrightSpring Health Services operates in the home and community-based health services sector, which is experiencing significant growth driven by an aging population, preference for in-home care, and a shift towards value-based care models. The company's strong performance, particularly in revenue and Adjusted EBITDA, suggests effective execution within this expanding market. Its focus on complex populations and integrated care across pharmacy and provider segments aligns with broader industry trends emphasizing comprehensive, patient-centric, and cost-effective healthcare solutions. The slight decrease in prescription volume, offset by higher revenue and gross profit per script, indicates a focus on higher-value prescriptions or improved pricing strategies, a common trend in the pharmacy sector.

Comparison to Industry Standards

• No specific comparable companies, projects, or industry benchmarks were mentioned in the filing to allow for a direct assessment against global standards.

Legal Proceedings

• Legal costs and settlements associated with certain historical PharMerica litigation matters, including the Silver matter, were finalized in 2024.

Related Party Transactions

• Kohlberg Kravis Roberts & Co, L.P. (KKR Stockholder) and certain members of management participated in a secondary offering of 15,000,000 shares of common stock. The interests of KKR Stockholder may conflict with other stockholders' interests in the future.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased guidance, and share repurchase. Potential for increased liquidity for selling shareholders through the secondary offering.
• Employees: Continued focus on operational excellence and service delivery suggests stability and ongoing opportunities.
• Customers/Patients: Emphasis on delivering high-quality, patient-centric, and lower-cost care indicates a positive impact on service recipients.
• Creditors: Leverage at 3.31x is a key metric for debt holders, indicating the company's debt management position.

Next Steps

• Host a conference call on October 28, 2025, at 4:30 p.m. Eastern Time to discuss Q3 2025 results.
• Close the planned divestiture of the Community Living business to Sevita in Q1 2026.
• Continue executing at a high level towards BrightSpring's goals for the remainder of 2025 and into 2026.

Key Dates

Recommendation

BrightSpring Health Services demonstrated robust financial growth in Q3 2025, with a significant increase in revenue and a positive shift from a net loss to net income. The Adjusted EBITDA also saw substantial growth, and management raised its full-year revenue guidance, signaling strong confidence in future performance. While prescription volume saw a minor dip, this was offset by improved revenue and gross profit per script, indicating enhanced profitability. The planned divestiture of the Community Living business, though delayed, is a strategic move to streamline operations and focus on core strengths. The overall strong performance and positive outlook suggest significant upside potential, making it an attractive investment for seasoned investors.

Keywords

BrightSpring Health Services, BTSG, Healthcare, Home Health, Community-Based Care, Pharmacy Solutions, Provider Services, Financial Results, Q3 2025, Revenue Guidance, Adjusted EBITDA, Divestiture, Secondary Offering